PT  - JOURNAL ARTICLE
AU  - Dimaschko, Juri
TI  - Superspreading as a Regular Factor of the COVID-19 Pandemic: I. A Two-Component Model
AID  - 10.1101/2020.06.29.20138008
DP  - 2020 Jan 01
TA  - medRxiv
PG  - 2020.06.29.20138008
4099  - http://medrxiv.org/content/early/2020/07/30/2020.06.29.20138008.short
4100  - http://medrxiv.org/content/early/2020/07/30/2020.06.29.20138008.full
AB  - We consider the impact of superspreading on the course of the COVID-19 epidemic. A two-component model of the epidemic has been developed, in which all infected are divided in two groups. The groups are asymptomatic superspreaders spreading the infection and sensitive persons which can only get infection. Once infected the sensitive exhibit clear symptoms and become isolated. It is shown that the ratio of increment of the number of daily cases in the beginning of the epidemic and decrement at the end of the epidemic is equal to the ratio of the spreading rates of the infection transmission from the superspreaders to potential superspreaders and to the sensitive persons, respectively. On the basis of data from 12 countries and territories it is found that the superspreaders transmit the infection to potential superspreaders approximately 4 times more often then to the sensitive persons. Specific measures to limit the epidemical incidence are proposed. The possibility of an allergic component in the disease is discussed.Competing Interest StatementThe authors have declared no competing interest.Funding StatementNo external funds was received.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:No approvals are requiredAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data are available.